These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 23569301

  • 1. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
    Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, Ye QH, Yu Y, Xu B, Qin XY, Xu J.
    J Clin Oncol; 2013 Jun 01; 31(16):1931-8. PubMed ID: 23569301
    [Abstract] [Full Text] [Related]

  • 2. Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for RAS Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled Trial.
    Tang W, Ren L, Liu T, Ye Q, Wei Y, He G, Lin Q, Wang X, Wang M, Liang F, Cui Y, Xu J.
    J Clin Oncol; 2020 Sep 20; 38(27):3175-3184. PubMed ID: 32749938
    [Abstract] [Full Text] [Related]

  • 3. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
    Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH.
    Lancet Oncol; 2010 Jan 20; 11(1):38-47. PubMed ID: 19942479
    [Abstract] [Full Text] [Related]

  • 4. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
    Wang DS, Ren C, Li SS, Fong WP, Wu XJ, Xiao J, Li BK, Zheng Y, Ding PR, Chen G, Qiu MZ, Wang ZQ, Wang FH, Luo HY, Wang F, Wang XZ, Wang LY, Xie DJ, Chen T, Li LR, Lu ZH, Zhai XH, Liu TS, Yuan Y, Chen JQ, Tan Q, Pan ZZ, Wan DS, Zhang R, Yuan YF, Xu RH, Li YH.
    PLoS Med; 2024 May 20; 21(5):e1004389. PubMed ID: 38728364
    [Abstract] [Full Text] [Related]

  • 5. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.
    Schwartzberg LS, Rivera F, Karthaus M, Fasola G, Canon JL, Hecht JR, Yu H, Oliner KS, Go WY.
    J Clin Oncol; 2014 Jul 20; 32(21):2240-7. PubMed ID: 24687833
    [Abstract] [Full Text] [Related]

  • 6. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J, Díaz-Rubio E.
    Clin Transl Oncol; 2010 Aug 20; 12(8):533-42. PubMed ID: 20709651
    [Abstract] [Full Text] [Related]

  • 7. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Stintzing S, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jäger E, Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V.
    Ann Oncol; 2012 Jul 20; 23(7):1693-9. PubMed ID: 22219013
    [Abstract] [Full Text] [Related]

  • 8. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
    Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Köhne CH.
    Ann Oncol; 2014 May 20; 25(5):1018-25. PubMed ID: 24585720
    [Abstract] [Full Text] [Related]

  • 9. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis.
    Ji JH, Park SH, Lee J, Kim TW, Hong YS, Kim KP, Kim SY, Baek JY, Kang HJ, Shin SJ, Shim BY, Park YS.
    Cancer Chemother Pharmacol; 2013 Jul 20; 72(1):223-30. PubMed ID: 23689915
    [Abstract] [Full Text] [Related]

  • 10. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
    Primrose J, Falk S, Finch-Jones M, Valle J, O'Reilly D, Siriwardena A, Hornbuckle J, Peterson M, Rees M, Iveson T, Hickish T, Butler R, Stanton L, Dixon E, Little L, Bowers M, Pugh S, Garden OJ, Cunningham D, Maughan T, Bridgewater J.
    Lancet Oncol; 2014 May 20; 15(6):601-11. PubMed ID: 24717919
    [Abstract] [Full Text] [Related]

  • 11. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S, Stift J, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T.
    Eur J Surg Oncol; 2015 Jul 20; 41(7):868-74. PubMed ID: 25865557
    [Abstract] [Full Text] [Related]

  • 12. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial.
    Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, Hatzidaki D, Voutsina A, Mavroudis D, Georgoulias V, Souglakos J.
    Br J Cancer; 2012 Dec 04; 107(12):1932-7. PubMed ID: 23169296
    [Abstract] [Full Text] [Related]

  • 13. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP, MRC COIN Trial Investigators.
    Lancet; 2011 Jun 18; 377(9783):2103-14. PubMed ID: 21641636
    [Abstract] [Full Text] [Related]

  • 14. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
    Malik H, Khan AZ, Berry DP, Cameron IC, Pope I, Sherlock D, Helmy S, Byrne B, Thompson M, Pulfer A, Davidson B.
    Eur J Surg Oncol; 2015 Apr 18; 41(4):499-505. PubMed ID: 25703078
    [Abstract] [Full Text] [Related]

  • 15. Conversion Chemotherapy for Technically Unresectable Colorectal Liver Metastases: A Retrospective, STROBE-Compliant, Single-Center Study Comparing Chemotherapy Alone and Combination Chemotherapy With Cetuximab or Bevacizumab.
    Basso M, Dadduzio V, Ardito F, Lombardi P, Strippoli A, Vellone M, Orlandi A, Rossi S, Cerchiaro E, Cassano A, Giuliante F, Barone C.
    Medicine (Baltimore); 2016 May 18; 95(20):e3722. PubMed ID: 27196492
    [Abstract] [Full Text] [Related]

  • 16. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study.
    Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T.
    J Clin Oncol; 2012 May 20; 30(15):1755-62. PubMed ID: 22473155
    [Abstract] [Full Text] [Related]

  • 17. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
    Brodowicz T, Ciuleanu TE, Radosavljevic D, Shacham-Shmueli E, Vrbanec D, Plate S, Mrsic-Krmpotic Z, Dank M, Purkalne G, Messinger D, Zielinski CC.
    Ann Oncol; 2013 Jul 20; 24(7):1769-1777. PubMed ID: 23559149
    [Abstract] [Full Text] [Related]

  • 18. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer.
    Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY.
    Clin Colorectal Cancer; 2015 Jun 20; 14(2):72-80. PubMed ID: 25982297
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.
    Clin Ther; 2011 Apr 20; 33(4):482-97. PubMed ID: 21635994
    [Abstract] [Full Text] [Related]

  • 20. Prospective analysis of KRAS wild-type patients with metastatic colorectal cancer using cetuximab plus FOLFIRI or FOLFOX4 treatment regimens.
    Huang MY, Chen MJ, Tsai HL, Kuo CH, Ma CJ, Hou MF, Chuang SC, Lin SR, Wang JY.
    Genet Mol Res; 2011 Oct 03; 10(4):3002-12. PubMed ID: 21968808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.